BT5528 + nivolumab

BT5528 + nivolumab is an experimental combination therapy evaluated in clinical trials for advanced solid tumors with high EphA2 expression. **BT5528** is a Bicycle Toxin Conjugate, consisting of a chemically synthesized bicyclic peptide that selectively targets the EphA2 tumor antigen and delivers a cytotoxin, monomethyl auristatin E (MMAE), directly to tumor cells, leading to cell death. **Nivolumab** is a monoclonal antibody that blocks programmed death-1 (PD-1), a checkpoint receptor on T cells, restoring immune system activity against cancer cells. The rationale for this combination is to simultaneously induce direct antitumor cytotoxicity while enhancing immune-mediated tumor clearance[1][2][4][5][7].